DTIL
NASDAQ
US
Precision BioSciences, Inc. - Common Stock
$5.82
▲ +$0.13
(+2.28%)
Vol 304K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$100.1M
ROE
-213.8%
Margin
-11977.4%
D/E
134.51
Beta
1.35
52W
$4–$9
Wall Street Consensus
10 analysts · Apr 20264
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
90.0%
Buy Rating
Price Chart
Similar Stocks
TNYA
Tenaya Therapeutics Inc
$154.0M
HRTX
Heron Therapeutics Inc
$238.4M
UNCY
Unicycive Therapeutics Inc
$124.0M
FATE
Fate Therapeutics Inc
$113.3M
SPRO
Spero Therapeutics Inc
$131.3M
CBUS
Cibus Inc
$94.5M
BDTX
Black Diamond Therapeutics Inc
P/E 6.4
$138.4M
KLRS
Kalaris Therapeutics Inc
$141.3M
AGEN
Agenus Inc
$106.8M
Earnings
Beat rate: 25.0%
Next Report
May 13, 2026
EPS Estimate: $-0.81
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.81 | — | — |
| Dec 2025 | $-0.55 | $1.05 | +$1.60 |
| Sep 2025 | $-1.37 | $-1.84 | $-0.47 |
| Jun 2025 | $-1.60 | $-2.13 | $-0.53 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -153.0% | -153.0% | -153.0% | -153.0% | -213.8% | -213.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -130666.7% | -6205.8% | -6205.8% | -6205.8% | -11977.4% | -11977.4% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 65.64 | 65.64 | 65.64 | 65.64 | 134.51 | 134.51 |
| Current Ratio | 5.18 | 5.18 | 5.18 | 5.18 | 3.45 | 3.45 |
Key Ratios
ROA (TTM)
-72.2%
P/S (TTM)
143.46
P/B
0.5
EPS (TTM)
$-8.40
CF/Share
$-0.62
Rev Growth 3Y
-15.9%
52W High
$8.82
52W Low
$3.61
$3.61
52-Week Range
$8.82
How does DTIL compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
DTIL valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
143.5
▲
1016%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.5
▼
79%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
DTIL profitability vs Biotechnology peers
ROE
-213.8%
▼
218%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-11977.4%
▼
4077%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-72.2%
▼
55%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
DTIL financial health vs Biotechnology peers
D/E ratio
134.5
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.5
▼
22%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.4
▲
39%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
DTIL fundamentals radar
DTIL
Peer median
Industry
DTIL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
DTIL vs peers: key metrics
Latest News
No related news yet